Review decision – July 2017
Decision to defer the review
TA306 was due to be considered for review “when the PIX306 trial results became available and at the latest in November 2016”.
PIX306 will compare the effectiveness of pixantrone plus rituximab with gemcitabine plus rituximab in patients with relapsed or refractory aggressive non-Hodgkin's B cell lymphoma who have already received a rituximab-containing regimen. The committee considered that the patient population in PIX306 would be relevant to its decision-making, because virtually all patients with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma in England and Wales will have previously received rituximab.
The results of PIX306 will now not be available until Q4 2017 at the earliest.
Consequently we have decided to defer the consideration of the review, which will now take place within 6 months of the publication of the results of PIX306.
This page was last updated: